Literature DB >> 3370644

Prediagnostic serum hormones and the risk of prostate cancer.

A Nomura1, L K Heilbrun, G N Stemmermann, H L Judd.   

Abstract

Serum samples were obtained from 6860 men during their study examination from 1971 to 1975. After a surveillance period of about 14 years, 98 incident cases of prostate cancer were identified. Their stored sera and that of 98 matched controls from the study population were tested for the following: testosterone, dihydrotestosterone, estrone, estradiol, and sex hormone globulin. There was a suggestion that serum dihydrotestosterone levels were lower and the testosterone/dihydrotestosterone ratios were higher in the prostate cancer cases compared with their controls. However, none of these associations or that of the other hormones was strongly significant. Further work is needed to clarify the relationship between sex hormones and prostate cancer risk.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3370644

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Racial differences in the androgen/androgen receptor pathway in prostate cancer.

Authors:  C A Pettaway
Journal:  J Natl Med Assoc       Date:  1999-12       Impact factor: 1.798

Review 2.  Nutrition and prostate cancer.

Authors:  L N Kolonel
Journal:  Cancer Causes Control       Date:  1996-01       Impact factor: 2.506

3.  Challenges with luteinizing hormone-releasing hormone agonists: flare and surge.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2004

4.  Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2003

5.  Smoking and prostate cancer in a multi-ethnic cohort.

Authors:  Adam B Murphy; Folasade Akereyeni; Yaw A Nyame; Mignonne C Guy; Iman K Martin; Courtney M P Hollowell; Kelly Walker; Rick A Kittles; Chiledum Ahaghotu
Journal:  Prostate       Date:  2013-07-03       Impact factor: 4.104

6.  Urinary estrogen metabolites and prostate cancer risk: a pilot study.

Authors:  Ourania Kosti; Xia Xu; Timothy D Veenstra; Ann W Hsing; Lisa W Chu; Lenka Goldman; Ionut Bebu; Sean Collins; Anatoly Dritschilo; John H Lynch; Radoslav Goldman
Journal:  Prostate       Date:  2010-09-30       Impact factor: 4.104

Review 7.  Andropause. Testosterone replacement therapy for aging men.

Authors:  J Bain
Journal:  Can Fam Physician       Date:  2001-01       Impact factor: 3.275

8.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

Review 9.  Androgen therapy in the aging male.

Authors:  Bruno Lunenfeld
Journal:  World J Urol       Date:  2003-10-24       Impact factor: 4.226

10.  Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.

Authors:  Andrew W Roddam; Naomi E Allen; Paul Appleby; Timothy J Key
Journal:  J Natl Cancer Inst       Date:  2008-01-29       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.